Pharmicell (005690) — Cash Flow Quality Index
Latest as of September 2025:
1.00x
Pharmicell (005690) has a Cash Flow Quality Index of 1.00x as of September 2025. Operating cash flow of ₩8.78 Billion exceeds net income of ₩8.78 Billion, indicating high earnings quality where cash backs reported profits. Explore debt repayment capacity of Pharmicell to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
1.00x
Operating CF / Net Income
Operating Cash Flow
₩8.78 Billion
KRW
Net Income
₩8.78 Billion
KRW
Data as of
Sep 2025
Most recent filing
Pharmicell Cash Flow Quality Index (2019–2024)
Historical Cash Flow Quality Index for Pharmicell across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 005690 cash generation efficiency.
Annual Cash Flow Quality Index for Pharmicell (2019–2024)
Year-by-year earnings quality comparison for Pharmicell.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | ₩3.50 Billion | ₩6.33 Billion | ▼ -83.3% |
| 2023 | 3.30x | ₩11.81 Billion | ₩3.58 Billion | ▲ +244.7% |
| 2022 | 0.96x | ₩7.91 Billion | ₩8.26 Billion | ▲ +273.4% |
| 2021 | -0.55x | ₩-5.22 Billion | ₩9.45 Billion | ▼ -132.3% |
| 2020 | 1.71x | ₩8.98 Billion | ₩5.24 Billion | ▲ +9962.0% |
| 2019 | -0.02x | ₩-75.50 Million | ₩4.35 Billion | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.